CRANFORD, N.J., June 26, 2020 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the Company has received a written response from the U.S. Food and Drug Administration (FDA) in regards to its pre-investigational new drug (PIND) application for its induced mesenchymal stem cells (iMSCs) to treat and reduce the severity of acute respiratory distress syndrome (ARDS) in patients with COVID-19.
The FDA acknowledged that the Company could apply for fast track designation and also provided Citius with the chemistry, manufacturing, and control (CMC) requirements for the proposed trials. The Company plans to initiate actions on the FDA's recommendations and follow up with the FDA with an Investigational New Drug (IND) application under the Coronavirus Treatment Acceleration Program (CTAP).
Myron Holubiak, Chief Executive Officer of Citius, commented, "We appreciate the FDA's thoughtful guidance on our unique, allogenic mesenchymal stem cells derived from induced pluripotent stem cells (iPSCs). We understand that iPSC-derived stem cells are not the same as adult-donor derived cells and, therefore, would require different proof of concept studies. Since we believe in the advantages of iPSC MSCs over donor-derived cells, we intend to develop assays recommended by the FDA and demonstrate the safety of these MSCs in our preclinical studies. We are committed to the successful completion of the required clinical trials to provide an effective and safe therapy for ARDS due to COVID-19."
About Citius Pharmaceuticals, Inc.Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visitwww.citiuspharma.com.
About Citius iMSCCitius's mesenchymal stem cell therapy product is derived from a human induced pluripotent stem cell (iPSC) line generated using a proprietary mRNA-based (non-viral) reprogramming process. The iMSCs produced from this clonal technique are differentiated from adult donor-derived MSCs (bone marrow, placenta, umbilical cord, adipose tissue, or dental pulp) by providing genetic homogeneity. In in-vitro studies, iMSCs exhibit superior potency and high cell viability. The iMSCs secrete immunomodulatory proteins that may reduce or prevent pulmonary symptoms associated with acute respiratory distress syndrome (ARDS) in patients with COVID-19. The Citius iMSC is an allogeneic (unrelated donor) mesenchymal stem-cell product manufactured by expanding material from a master cell bank.
About Acute Respiratory Distress Syndrome (ARDS)ARDS is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. ARDS is a rapidly progressive disease that occurs in critically ill patients most notably now in those diagnosed with COVID-19. ARDS affects approximately 200,000 patients per year in the U.S., exclusive of the current COVID-19 pandemic, and has a 30% to 50% mortality rate. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.
About Coronavirus Treatment Acceleration Program (CTAP)In response to the pandemic, the FDA has created an emergency program called the Coronavirus Treatment Acceleration Program (CTAP) to accelerate the development of treatments for COVID-19. By redeploying staff, the FDA is responding to COVID-19-related requests and reviewing protocols within 24 hours of receipt. The FDA said CTAP "uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful." In practice, that means developers of potential treatments for COVID-19 would benefit from an unusually faster track at the FDA to shorten wait times at multiple steps of the process.
Safe Harbor
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risk of successfully negotiating a license agreement for a potential ARDS therapy with Novellus, Inc. within the option period; the ability to access the FDA's CTAP program for our planned ARDS therapy; risks associated with developing our product candidates, including any licensed from Novellus, Inc., including that preclinical results may not be predictive of clinical results and our ability to file an IND for such candidates; our need for substantial additional funds; risks associated with conducting our Phase 3 trial for Mino-Lok, including completing patient enrollment, opening study sites and achieving the required number of catheter failure events; the estimated markets for our product candidates, including those for ARDS, and the acceptance thereof by any market; risks related to our growth strategy; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to attract, integrate, and retain key personnel; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Contact:
Andrew Scott Vice President, Corporate Development (O) 908-967-6677 x105 [emailprotected]
SOURCE Citius Pharmaceuticals, Inc.
- 10. The Promise of Induced Pluripotent Stem Cells (iPSCs ... [Last Updated On: May 5th, 2015] [Originally Added On: May 5th, 2015]
- What are induced pluripotent stem cells? [Stem Cell ... [Last Updated On: May 5th, 2015] [Originally Added On: May 5th, 2015]
- Embryonic and induced pluripotent stem cells Part 6 - Video [Last Updated On: May 5th, 2015] [Originally Added On: May 5th, 2015]
- Embryonic and induced pluripotent stem cells Part 2 - Video [Last Updated On: May 5th, 2015] [Originally Added On: May 5th, 2015]
- Embryonic and induced pluripotent stem cells Part 5 - Video [Last Updated On: May 5th, 2015] [Originally Added On: May 5th, 2015]
- Embryonic and induced pluripotent stem cells Part 3 - Video [Last Updated On: May 5th, 2015] [Originally Added On: May 5th, 2015]
- Embryonic and induced pluripotent stem cells Part 4 - Video [Last Updated On: May 5th, 2015] [Originally Added On: May 5th, 2015]
- Embryonic and induced pluripotent stem cells Part 1 - Video [Last Updated On: May 5th, 2015] [Originally Added On: May 5th, 2015]
- piggyBac transposition reprograms fibroblasts to induced ... [Last Updated On: May 8th, 2015] [Originally Added On: May 8th, 2015]
- Induced Pluripotent Stem Cells (IPSCs) - HowStuffWorks [Last Updated On: May 27th, 2015] [Originally Added On: May 27th, 2015]
- Pluripotency of Induced Pluripotent Stem Cells [Last Updated On: May 27th, 2015] [Originally Added On: May 27th, 2015]
- Induced stem cells - Wikipedia, the free encyclopedia [Last Updated On: May 27th, 2015] [Originally Added On: May 27th, 2015]
- Induced Pluripotent Stem Cells (iPS) | UCLA Broad Stem ... [Last Updated On: May 27th, 2015] [Originally Added On: May 27th, 2015]
- iPS cells and reprogramming: turn any cell of the body ... [Last Updated On: June 2nd, 2015] [Originally Added On: June 2nd, 2015]
- induced pluripotent stem cells - RCN Corporation [Last Updated On: July 3rd, 2015] [Originally Added On: July 3rd, 2015]
- Generating Mice from Induced Pluripotent Stem Cells | Protocol [Last Updated On: July 3rd, 2015] [Originally Added On: July 3rd, 2015]
- Stem Cell Key Terms | California's Stem Cell Agency [Last Updated On: July 31st, 2015] [Originally Added On: July 31st, 2015]
- Cell potency - Wikipedia, the free encyclopedia [Last Updated On: July 31st, 2015] [Originally Added On: July 31st, 2015]
- Induced pluripotent stem cell therapy - Wikipedia, the ... [Last Updated On: August 3rd, 2015] [Originally Added On: August 3rd, 2015]
- Glossary [Stem Cell Information] [Last Updated On: August 15th, 2015] [Originally Added On: August 15th, 2015]
- STEMCELL Technologies Inc. Enters a Licensing Agreement ... [Last Updated On: August 29th, 2015] [Originally Added On: August 29th, 2015]
- Pluripotent Stem Cells 101 | Boston Children's Hospital [Last Updated On: September 10th, 2015] [Originally Added On: September 10th, 2015]
- COMPLETE 2015-16 INDUCED PLURIPOTENT STEM CELL INDUSTRY REPORT [Last Updated On: October 20th, 2015] [Originally Added On: October 20th, 2015]
- Complete 2015-16 Induced Pluripotent Stem Cell Industry ... [Last Updated On: October 20th, 2015] [Originally Added On: October 20th, 2015]
- Derivation of Ethnically Diverse Human Induced Pluripotent ... [Last Updated On: October 21st, 2015] [Originally Added On: October 21st, 2015]
- Purest yet liver-like cells generated from induced ... [Last Updated On: August 30th, 2016] [Originally Added On: August 30th, 2016]
- World Induced Pluripotent Stem Cells Market - Opportunities ... [Last Updated On: September 18th, 2016] [Originally Added On: September 18th, 2016]
- Induced Pluripotent Stem Cells Market 2016: Hepatocytes ... [Last Updated On: September 18th, 2016] [Originally Added On: September 18th, 2016]
- The Promise of Induced Pluripotent Stem Cells (iPSCs ... [Last Updated On: September 23rd, 2016] [Originally Added On: September 23rd, 2016]
- Induced Pluripotent Stem Cells: 10 Years After the ... [Last Updated On: September 28th, 2016] [Originally Added On: September 28th, 2016]
- Induced Pluripotent Stem Cell Initiative | California's ... [Last Updated On: October 7th, 2016] [Originally Added On: October 7th, 2016]
- Stem Cell Basics VI. | stemcells.nih.gov [Last Updated On: October 12th, 2016] [Originally Added On: October 12th, 2016]
- Induced stem cells - Wikipedia [Last Updated On: October 18th, 2016] [Originally Added On: October 18th, 2016]
- Induced Pluripotent Stem Cells (iPS) - UCLA Broad Stem Cell [Last Updated On: October 21st, 2016] [Originally Added On: October 21st, 2016]
- Induced Pluripotent Stem Cells: A New Frontier for Stem ... [Last Updated On: October 27th, 2016] [Originally Added On: October 27th, 2016]
- Induced pluripotent stem cells and Parkinson's disease ... [Last Updated On: October 27th, 2016] [Originally Added On: October 27th, 2016]
- Generation of Induced Pluripotent Stem Cells with ... [Last Updated On: November 3rd, 2016] [Originally Added On: November 3rd, 2016]
- Generation of Neural Crest-Like Cells From Human ... [Last Updated On: November 14th, 2016] [Originally Added On: November 14th, 2016]
- Induced pluripotent stem-cell therapy - Wikipedia [Last Updated On: November 18th, 2016] [Originally Added On: November 18th, 2016]
- Generation of germline-competent induced pluripotent stem ... [Last Updated On: November 22nd, 2016] [Originally Added On: November 22nd, 2016]
- Induced pluripotent stem cell models from X-linked ... [Last Updated On: November 23rd, 2016] [Originally Added On: November 23rd, 2016]
- Live Cell Imaging of Induced Pluripotent Stem Cell ... [Last Updated On: November 23rd, 2016] [Originally Added On: November 23rd, 2016]
- Induced Pluripotent Stem Cells - cellapplications.com [Last Updated On: November 23rd, 2016] [Originally Added On: November 23rd, 2016]
- Why Induced Pluripotent Stem Cells Are Vital for Glaucoma ... [Last Updated On: December 3rd, 2016] [Originally Added On: December 3rd, 2016]
- Stem Cell Glossary - stemcells.nih.gov [Last Updated On: December 5th, 2016] [Originally Added On: December 5th, 2016]
- Clinical potential of human-induced pluripotent stem cells ... [Last Updated On: December 5th, 2016] [Originally Added On: December 5th, 2016]
- Induced stem cells - Wikiversity [Last Updated On: December 17th, 2016] [Originally Added On: December 17th, 2016]
- Induced pluripotent stem cell Wikipedia StemCell Therapy [Last Updated On: December 17th, 2016] [Originally Added On: December 17th, 2016]
- Embryonic stem (ES) cells and induced pluripotent stem ... [Last Updated On: January 17th, 2017] [Originally Added On: January 17th, 2017]
- Induced Pluripotent Stem Cell Repository | California's ... [Last Updated On: January 23rd, 2017] [Originally Added On: January 23rd, 2017]
- induced pluripotent stem cells - eurostemcell.org [Last Updated On: January 27th, 2017] [Originally Added On: January 27th, 2017]
- When C9ORF72 Silences U2, Spliceosomes Can't Find What They ... - Alzforum [Last Updated On: July 1st, 2017] [Originally Added On: July 1st, 2017]
- The Stem Cell Revolution - Seeking Alpha [Last Updated On: July 1st, 2017] [Originally Added On: July 1st, 2017]
- Evotec in neurology iPSC drug discovery collaboration with stem-cell specialist Censo - FierceBiotech [Last Updated On: July 1st, 2017] [Originally Added On: July 1st, 2017]
- Treating Asthma with Stem Cells | Technology Networks - Technology Networks [Last Updated On: July 1st, 2017] [Originally Added On: July 1st, 2017]
- Embryonic stem cells to be available for medical use in Japan by next March - The Japan Times [Last Updated On: July 5th, 2017] [Originally Added On: July 5th, 2017]
- This Study Could Help Extend the Human Lifespan - Futurism [Last Updated On: July 8th, 2017] [Originally Added On: July 8th, 2017]
- Grnenthal Group: Launch of the Project - Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain ... - PR Newswire (press release) [Last Updated On: July 8th, 2017] [Originally Added On: July 8th, 2017]
- The Global Market for Induced Pluripotent Stem Cells (iPSCs) should reach $3.6 Billion in 2021, Increasing at a CAGR ... - Business Wire (press... [Last Updated On: July 8th, 2017] [Originally Added On: July 8th, 2017]
- SBP Scientist Receives Prestigious WM Keck Foundation Grant - Newswise (press release) [Last Updated On: July 11th, 2017] [Originally Added On: July 11th, 2017]
- Is it time to start worrying about conscious human mini-brains? - PLoS Blogs (blog) [Last Updated On: August 2nd, 2017] [Originally Added On: August 2nd, 2017]
- A New Epigenetic Barrier to Induced Pluripotent Stem Cells - WhatIsEpigenetics.com [Last Updated On: August 2nd, 2017] [Originally Added On: August 2nd, 2017]
- What are induced pluripotent stem cells or iPS cells? - Stem ... [Last Updated On: August 2nd, 2017] [Originally Added On: August 2nd, 2017]
- Stem Cell Glossary - Closer Look at Stem Cells [Last Updated On: August 2nd, 2017] [Originally Added On: August 2nd, 2017]
- CRISPR Corrects Disease Mutation in Human Embryos - Genetic Engineering & Biotechnology News (blog) [Last Updated On: August 3rd, 2017] [Originally Added On: August 3rd, 2017]
- World's 1st trial of drug developed from iPS cells to begin - Japan ... - Japan Today [Last Updated On: August 3rd, 2017] [Originally Added On: August 3rd, 2017]
- ASU grad students' lab skills help earn funding for cutting-edge biomedical research - Arizona State University [Last Updated On: August 10th, 2017] [Originally Added On: August 10th, 2017]
- How Food Preservatives May Disrupt Human Hormones - Laboratory Equipment [Last Updated On: August 10th, 2017] [Originally Added On: August 10th, 2017]
- Dopaminergic neurons derived from iPSCs in non-human primate model - Phys.Org [Last Updated On: August 12th, 2017] [Originally Added On: August 12th, 2017]
- Artificial Blood Vessels Mimic Rare Accelerated Aging Disease - Duke Today [Last Updated On: August 15th, 2017] [Originally Added On: August 15th, 2017]
- Induced Pluripotent Stem Cells Market Demands, Trends, Growth ... - MilTech [Last Updated On: August 15th, 2017] [Originally Added On: August 15th, 2017]
- induced pluripotent stem cell (iPS cell) | biology ... [Last Updated On: August 15th, 2017] [Originally Added On: August 15th, 2017]
- Induced Pluripotent Stem Cells: Global Markets Report 2017-2021 [Last Updated On: August 15th, 2017] [Originally Added On: August 15th, 2017]
- MESO-BRAIN initiative receives 3.3million to replicate brain's neural networks through 3D nanoprinting - Cordis News [Last Updated On: August 15th, 2017] [Originally Added On: August 15th, 2017]
- Global Induced Pluripotent Stem Cells Market: HTF Market [Last Updated On: August 15th, 2017] [Originally Added On: August 15th, 2017]
- Induced Pluripotent Stem Cells in Global Effort to ... [Last Updated On: August 15th, 2017] [Originally Added On: August 15th, 2017]
- How Do We Get Pluripotent Stem Cells? | Boston Children's ... [Last Updated On: August 15th, 2017] [Originally Added On: August 15th, 2017]
- Fertile offspring produced from sterile mice using iPS cells - Kyodo News Plus [Last Updated On: August 20th, 2017] [Originally Added On: August 20th, 2017]
- Brain Spheroids Hatch Mature Astrocytes | ALZFORUM - Alzforum [Last Updated On: August 20th, 2017] [Originally Added On: August 20th, 2017]
- Breakthrough in Gene Editing Comes as Scientists Correct Disease-Causing Mutation in Human Embryo - TrendinTech [Last Updated On: August 20th, 2017] [Originally Added On: August 20th, 2017]